Your Partner in Innovative Cancer Care

Together with you – the healthcare professional in practice or training – we’re finding the answers, insights, and treatment options that people with cancer deserve.

How to Refer a Patient

Memorial Sloan Kettering’s Patient Access Service is an easy way for doctors to refer a patient to a Memorial Sloan Kettering specialist. Find helpful phone numbers and other resources.

Learn more

Fellowships

Our renowned fellowship programs prepare doctors for leadership roles in the care of people with cancer around the world.

Clinical Trials

At any one time Memorial Sloan Kettering is running hundreds of clinical trials. Through these studies we can improve care for people with all types of cancer. Browse the MSK clinical trials that are currently enrolling new patients.

View all clinical trials
Prediction Tools

MSK’s researchers have developed prediction tools known as nomograms. These tests can help people with cancer and doctors make treatment decisions. The tools can be used to predict cancer outcomes. Nomograms also assess an individual’s risk based on the characteristics of their specific disease.

View all nomograms
Clinical Updates & Insights

Get the latest updates from MSK doctors. Read about new treatments, clinical trials, and innovations in detecting and treating many cancers.

Browse clinical updates

Clinical Update

What Comes First — Neoadjuvant Chemotherapy or Re-Resection for Patients with Incidental Gallbladder Cancer?

At Memorial Sloan Kettering Cancer Center, more than half of patients with gallbladder cancer are diagnosed incidentally following elective cholecystectomy for assumed benign disease. The traditional treatment approach for these patients is re-resection to achieve a cure.

Clinical Update

Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Improved understanding of the biology and molecular subtypes of non-small cell lung cancer (NSCLC) has led to the development of several biomarker-targeted therapies for patients with locally advanced and metastatic disease.

Clinical Update

Rise of the Mutant Clones: A Newly Recognized Risk Factor for CVD

Up to 20 percent of people over the age of 70 have clonal hematopoiesis of indeterminate potential (CHIP), a condition that carries twice the risk of coronary heart disease and ischemic stroke, and worse outcomes after heart failure — independent of traditional cardiovascular risk factors.